Atassi MZ[au] - Search Results

Year	Number of Results
1959	2
1961	2
1962	2
1964	2
1965	2
1966	4
1967	5
1968	4
1969	6
1970	8
1971	6
1972	6
1973	8
1974	6
1975	11
1976	8
1977	7
1978	12
1979	13
1980	12
1981	16
1982	13
1983	11
1984	9
1985	10
1986	10
1987	12
1988	9
1989	11
1990	9
1991	6
1992	9
1993	7
1994	6
1995	4
1996	3
1997	5
1998	7
1999	2
2000	3
2001	1
2002	2
2004	3
2005	7
2006	8
2007	7
2008	5
2009	1
2010	6
2011	13
2012	7
2014	3
2015	5
2016	3
2017	7
2018	1
2022	0

1

Deitiker P, Atassi MZ. Deitiker P, et al. Among authors: atassi mz. Crit Rev Immunol. 2015;35(3):203-51. doi: 10.1615/critrevimmunol.2015014510. Crit Rev Immunol. 2015. PMID: 26559228 Review.

2

Molecular mechanisms of autoimmunity.

Atassi MZ, Casali P. Atassi MZ, et al. Autoimmunity. 2008 Mar;41(2):123-32. doi: 10.1080/08916930801929021. Autoimmunity. 2008. PMID: 18324481 Review.

3

Non-MHC genes linked to autoimmune disease.

Deitiker P, Atassi MZ. Deitiker P, et al. Among authors: atassi mz. Crit Rev Immunol. 2012;32(3):193-285. doi: 10.1615/critrevimmunol.v32.i3.10. Crit Rev Immunol. 2012. PMID: 23176726 Review.

4

Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions.

Atassi MZ. Atassi MZ. Toxicon. 2015 Dec 1;107(Pt A):50-8. doi: 10.1016/j.toxicon.2015.06.003. Epub 2015 Jun 16. Toxicon. 2015. PMID: 26086358 Review.

5

Basic immunological aspects of botulinum toxin therapy.

Atassi MZ. Atassi MZ. Mov Disord. 2004 Mar;19 Suppl 8:S68-84. doi: 10.1002/mds.20020. Mov Disord. 2004. PMID: 15027058 Review.

6

T-cell recognition and antigen presentation of myoglobin.

Atassi MZ, Bixler GS Jr. Atassi MZ, et al. Adv Exp Med Biol. 1987;225:65-87. doi: 10.1007/978-1-4684-5442-0_6. Adv Exp Med Biol. 1987. PMID: 3331065 Review.

7

Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition.

Aoki KR, Smith LA, Atassi MZ. Aoki KR, et al. Among authors: atassi mz. Crit Rev Immunol. 2010;30(2):167-87. doi: 10.1615/critrevimmunol.v30.i2.50. Crit Rev Immunol. 2010. PMID: 20370628 Review.

8

Targeting the antigen-binding site of HLA-restricting alleles in treatment of autoimmune disease.

Oshima M, Deitiker P, Atassi MZ. Oshima M, et al. Among authors: atassi mz. Crit Rev Immunol. 2007;27(3):271-88. doi: 10.1615/critrevimmunol.v27.i3.60. Crit Rev Immunol. 2007. PMID: 18197821 Review.

9

Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action.

Atassi MZ, Dolimbek BZ, Steward LE, Aoki KR. Atassi MZ, et al. Crit Rev Immunol. 2007;27(4):319-41. doi: 10.1615/critrevimmunol.v27.i4.30. Crit Rev Immunol. 2007. PMID: 18197812 Review.

10

Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action.

Atassi MZ. Atassi MZ. Toxicon. 2009 Oct;54(5):600-13. doi: 10.1016/j.toxicon.2009.02.034. Epub 2009 Mar 11. Toxicon. 2009. PMID: 19285100 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results